N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
暂无分享,去创建一个
O. Elemento | Noah Dephoure | A. Sboner | H. Beltran | Jindan Yu | D. Rickman | V. Conteduca | C. Barbieri | N. Brady | J. Paik | L. Puca | E. Dardenne | B. Robinson | R. Bareja | Adeline Berger | Alyssa M Bagadion | M. Augello | Adnan Ahmed | I. Hwang | Xiaodong Lu | Noah E. Dephoure | Michael A. Augello | Alyssa M. Bagadion
[1] T. Graeber,et al. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage , 2018, Science.
[2] S. Begum,et al. Sequence Alignment , 2018, Beginners Guide to Bioinformatics for High Throughput Sequencing.
[3] T. Graeber,et al. Re: A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers. , 2019, The Journal of urology.
[4] Joshua M. Stuart,et al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Dong Gao,et al. Patient derived organoids to model rare prostate cancer phenotypes , 2018, Nature Communications.
[6] Zhiguo Zhang,et al. Asf1a resolves bivalent chromatin domains for the induction of lineage-specific genes during mouse embryonic stem cell differentiation , 2018, Proceedings of the National Academy of Sciences.
[7] Zhihua Liu,et al. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 , 2018, Proceedings of the National Academy of Sciences.
[8] Joshua M. Stuart,et al. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. , 2018, Cell.
[9] Ryan D. Chow,et al. Developmental History Provides a Roadmap for the Emergence of Tumor Plasticity. , 2018, Developmental cell.
[10] D. Rickman,et al. The Expanding World of N-MYC-Driven Tumors. , 2018, Cancer discovery.
[11] Donald R. Polaski,et al. Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma , 2018, Nature Genetics.
[12] D. Rickman,et al. Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle , 2017, Cell reports.
[13] Michael D. Nyquist,et al. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.
[14] Dong Chen,et al. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis , 2017, Blood Cancer Journal.
[15] Takafumi N. Yamaguchi,et al. TMPRSS2–ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer , 2017, Nature Genetics.
[16] M. Rubin,et al. Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. , 2017, Cancer discovery.
[17] M. Rubin,et al. Biology and evolution of poorly differentiated neuroendocrine tumors , 2017, Nature Medicine.
[18] Kristofer C. Berrett,et al. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. , 2017, Cancer cell.
[19] K. Plath,et al. Cbx3 maintains lineage specificity during neural differentiation. , 2017, Genes & development.
[20] A. Brunet,et al. Single-Cell Transcriptomic Analysis Defines Heterogeneity and Transcriptional Dynamics in the Adult Neural Stem Cell Lineage. , 2017, Cell reports.
[21] Henry W. Long,et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.
[22] M. Rubin,et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.
[23] M. Rubin,et al. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. , 2017, Cancer discovery.
[24] U. Schüller,et al. Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells , 2016, Oncotarget.
[25] Kaitlyn M. Gayvert,et al. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. , 2016, Cancer cell.
[26] E. Wolf,et al. The ubiquitin ligase HUWE1 regulates hematopoietic stem cell maintenance and lymphoid commitment , 2016, Nature immunology.
[27] J. Wolf,et al. Different promoter affinities account for specificity in MYC-dependent gene regulation , 2016, eLife.
[28] A. Gazdar,et al. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer , 2016, Genes & development.
[29] Fidel Ramírez,et al. deepTools2: a next generation web server for deep-sequencing data analysis , 2016, Nucleic Acids Res..
[30] Joshua M. Stuart,et al. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. , 2016, Cancer cell.
[31] Matteo Benelli,et al. Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.
[32] J. Carroll,et al. Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes , 2016, Nature Protocols.
[33] Jindan Yu,et al. FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression , 2016, Oncogene.
[34] K. Baggerly,et al. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers , 2015, Clinical Cancer Research.
[35] Henry W. Long,et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis , 2015, Nature Genetics.
[36] Vladimir Vacic,et al. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. , 2015, JAMA oncology.
[37] P. Nelson,et al. SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.
[38] G. Getz,et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer , 2015, Nature Communications.
[39] F. Westermann,et al. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies , 2014, Oncogene.
[40] Ximing J. Yang,et al. Neuroendocrine differentiation of prostate cancer: a review. , 2014, American journal of clinical and experimental urology.
[41] Eugenia G. Giannopoulou,et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer , 2014, Nature Communications.
[42] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[43] M. Kloor,et al. Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases , 2014, Virchows Archiv.
[44] Raluca Gordân,et al. Sequence specificity incompletely defines the genome-wide occupancy of Myc , 2014, Genome Biology.
[45] Paul Theodor Pyl,et al. HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.
[46] M. Rubin,et al. Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.
[47] Björn Usadel,et al. Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..
[48] W. Weiss,et al. The prenatal origins of cancer , 2014, Nature Reviews Cancer.
[49] C. Rudin,et al. MYC, MAX, and small cell lung cancer. , 2014, Cancer discovery.
[50] I. Huijbers,et al. Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells , 2014, EMBO molecular medicine.
[51] Wennuan Liu,et al. Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma , 2013, Clinical Cancer Research.
[52] D. Zheng,et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss , 2013, Nature Medicine.
[53] Gerald C. Chu,et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. , 2013, Cancer research.
[54] M. Rubin,et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. , 2013, Neoplasia.
[55] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[56] Scott L. Pomeroy,et al. Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.
[57] Herbert Waldmann,et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer , 2012, Proceedings of the National Academy of Sciences.
[58] K. Cibulskis,et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.
[59] P. Northcott,et al. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. , 2012, Cancer cell.
[60] Chi V Dang,et al. MYC on the Path to Cancer , 2012, Cell.
[61] Steven L Salzberg,et al. Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.
[62] David R. Kelley,et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.
[63] Andrew E. Jaffe,et al. Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments , 2022 .
[64] P. Troncoso,et al. Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features , 2011, Clinical Cancer Research.
[65] A. Ashworth,et al. Molecular profiling reveals frequent gain of MYCN and anaplasia‐specific loss of 4q and 14q in wilms tumor , 2011, Genes, chromosomes & cancer.
[66] M. Gerstein,et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. , 2011, Cancer discovery.
[67] R. M. Simpson,et al. Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. , 2011, The American journal of pathology.
[68] P. Troncoso,et al. Neuroendocrine prostate cancer xenografts with large‐cell and small‐cell features derived from a single patient's tumor: Morphological, immunohistochemical, and gene expression profiles , 2011, The Prostate.
[69] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[70] Chris Sander,et al. MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors , 2011, PloS one.
[71] A. Skoudy,et al. Pancreatic Ductal Adenocarcinoma and Transcription Factors: Role of c-Myc , 2011, Journal of gastrointestinal cancer.
[72] Edward L. Huttlin,et al. A Tissue-Specific Atlas of Mouse Protein Phosphorylation and Expression , 2010, Cell.
[73] C. Bieberich,et al. MYC and Prostate Cancer. , 2010, Genes & cancer.
[74] C. Glass,et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.
[75] Aaron R. Quinlan,et al. BIOINFORMATICS APPLICATIONS NOTE , 2022 .
[76] Clifford A. Meyer,et al. Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer , 2009, Cell.
[77] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[78] Clifford A. Meyer,et al. Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.
[79] Jun Luo,et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.
[80] T. Mikkelsen,et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells , 2008, Nature.
[81] Georgia Panagiotakos,et al. Isolation and directed differentiation of neural crest stem cells derived from human embryonic stem cells , 2007, Nature Biotechnology.
[82] K. Pienta,et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. , 2007, Molecular cell.
[83] T. Mikkelsen,et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells , 2007, Nature.
[84] Steven P Gygi,et al. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.
[85] Cheng Li,et al. Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.
[86] David C. Corney,et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.
[87] James A. Cuff,et al. A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells , 2006, Cell.
[88] G. Grosveld,et al. Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9. , 2005, Blood.
[89] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[90] Yong-jie Lu,et al. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] R. Puri,et al. Gene expression in human embryonic stem cell lines: unique molecular signature. , 2004, Blood.
[92] T. Graeber,et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.
[93] M. Mann,et al. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. , 2003, Analytical chemistry.
[94] K. Sayama,et al. Different effects of dominant negative mutants of desmocollin and desmoglein on the cell-cell adhesion of keratinocytes. , 2000, Journal of cell science.
[95] F. Davis,et al. The conditional probability of survival of patients with primary malignant brain tumors , 1999, Cancer.
[96] M. Cole,et al. The Novel ATM-Related Protein TRRAP Is an Essential Cofactor for the c-Myc and E2F Oncoproteins , 1998, Cell.
[97] G. Mohapatra,et al. Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.
[98] Mark L. Greenberg,et al. MYCN gene amplification in rhabdomyosarcoma , 1994, Cancer.
[99] T. Salmi,et al. L-myc and N-myc in hematopoietic malignancies. , 1993, Leukemia & lymphoma.
[100] K. Klempnauer,et al. Sequence-specific DNA binding by Myc proteins. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[101] R. Eisenman,et al. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. , 1991, Science.
[102] M. Lohuizen,et al. N‐myc is frequently activated by proviral insertion in MuLV‐induced T cell lymphomas. , 1989, The EMBO journal.
[103] S. Baylin,et al. Gene amplification of c-myc and N-myc in small cell carcinoma of the lung. , 1986, Science.
[104] J. Battey,et al. Human small-cell lung cancers show amplification and expression of the N-myc gene. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[105] J. Garson,et al. N-MYC AMPLIFICATION IN MALIGNANT ASTROCYTOMA , 1985, The Lancet.
[106] Wen-Hwa Lee,et al. Expression and amplification of the N-myc gene in primary retinoblastoma , 1984, Nature.
[107] McLellan Gh. Letter: SI units. , 1975 .